Sustainability

"TE-A-TE" Creates Smiles

Hisamitsu cherishes the "TE-A-TE" culture.
What lies beneath "TE-A-TE" is your compassion for your loved ones.
Such compassion is the starting point of our “patch treatment culture,”
which we have emphasized since our establishment.

One way to spread "TE-A-TE" culture throughout the world is to promote
"patch treatment culture," but our corporate responsibilities are not limited to that.

It is our mission and responsibility as long as it is filled with enthusiasm for
"TE-A-TE" and concerned with customer satisfaction, even if it is in the realm of
non-profit operations or disease/injury prevention.

By contributing to creating happy smiles through a
compassionate "TE-A-TE" culture, we will strive to achieve a
favorable cycle of solving social problems and realizing our
corporate group’s growth.

image

Hisamitsu Pharmaceutical has been selected as a constituent of the FTSE Blossom Japan Sector Relative Index.

Created by global index provider FTSE Russell, the FTSE Blossom Japan Sector Relative Index reflects the
performance of Japanese companies that demonstrate strong environmental, social and governance (ESG)
practices relative to their respective sectors and is designed to be sector neutral.In addition, to
facilitate the transition to a low-carbon economy, it includes only those companies whose improvement
efforts are evaluated by the TPI (Transition Pathway Initiative) Management Quality Score, especially
for companies with high greenhouse gas emissions.

This index has been adopted as one of the ESG indexes followed by the Government Pension Investment Fund (GPIF).

FTSE Russell (registered trademark of FTSE International Limited and Frank Russell Company) hereby certifies that Hisamitsu Pharmaceutical, as a result of a third-party survey, has met the requirements for inclusion in the FTSE Blossom Japan Sector Relative Index and has become a constituent of the index. The FTSE Blossom Japan Sector Relative Index is widely used to create and evaluate sustainable investment funds and other financial products.

Hisamitsu Pharmaceutical was certified with three stars in the Nikkei SDGs Management Survey 2023, and this was reported in the Nihon Keizai Shimbun.

NIKKEI SDGs 2022

The Nikkei SDGs Management Survey, conducted by Nikkei Inc. since 2019, rates companies’ commitment to the Sustainable Development Goals (SDGs) in the four categories of “SDGs strategy/economic value,” “social value,” “environmental value,” and “governance.” The score of each company is converted into a deviation value, and a deviation value of 70 or higher is set as 5.0 stars. For lower deviations, the rating changes by 0.5 stars in increments of five deviation values.

PAGETOP